Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

Haematologica

Volumn 96, Issue 6, 2011, Pages 845-853

  Hornakova, Tekla ^a,b   Springuel, Lorraine ^a,b   Devreux, Julien ^a,b   Dusa, Alexandra ^a,b   Constantinescu, Stefan N ^a,b   Knoops, Laurent ^a,b,c   Renauld, Jean Christophe ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Inhibitors; JAK; Mutations; STAT; Tyrosine kinase

Indexed keywords

CMP6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; RUXOLITINIB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME INHIBITION; GENE MUTATION; MOUSE; MUTANT; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PROTEIN DOMAIN; WILD TYPE;

ADENOSINE TRIPHOSPHATE; ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; DRUG RESISTANCE, NEOPLASM; GENE ORDER; JANUS KINASE 1; JANUS KINASE 2; MICE; MODELS, MOLECULAR; MUTATION; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 79958061888     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036350     Document Type: Article

References (34)

1. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109(9):1139-42.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8.
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61.
4. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005; 106 (10):3377-9.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-90.
6. Schindler C, Levy DE, Decker T. JAKSTAT signaling: from interferons to cytokines. J Biol Chem. 2007;282 (28): 20059-63.
7. Haan C, Is'harc H, Hermanns HM, Schmitz-Van De Leur H, Kerr IM, Heinrich PC, et al. Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. J Biol Chem. 2001;276 (40):37451-8.
8. Wilks AF. The JAK kinases: not just another kinase drug discovery target. Semin Cell. Dev Biol 2008;19(4):319-28.
9. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008;205(4):751-8.
10. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008;14(12):3716-21.
11. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, et al. JAK mutations in highrisk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106(23):9414-8.
12. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363 (12):1117-27.
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293 (5531): 876-80.
14. Demoulin JB, Uyttenhove C, Lejeune D, Mui A, Groner B, Renauld JC. STAT5 activation is required for interleukin-9- dependent growth and transformation of lymphoid cells. Cancer Res 2000;60 (14):3971-7.
15. Demoulin JB, Uyttenhove C, Van Roost E, DeLestre B, Donckers D, Van Snick J, et al. A single tyrosine of the interleukin- 9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol 1996;16(9):4710-6.
16. Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. JAK kinases overexpression promotes in vitro cell transformation. Oncogene 2008;27 (11):1511-9.
17. Hornakova T, Chiaretti S, Lemaire MM, Foa R, Ben Abdelali R, Asnafi V, et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010; 115(16):3287-95.
18. Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem 2009;284(11):6773-81.
19. Dusa A, Staerk J, Elliott J, Pecquet C, Poirel HA, Johnston JA, et al. Sub stitution of pseudokinase domain residue Val- 617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 2008;283(19): 12941-8.
20. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, et al. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 2003;12(5):1239-50.
21. Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009;387(1):219-32.
22. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004;25(13):1605-12.
23. Asnafi V, Le Noir S, Lhermitte L, Gardin C, Legrand F, Vallantin X, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol 2009;148(1):178-9.
24. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001;14(1):27-37.
25. Dusa A, Mouton C, Pecquet C, Herman M, Constantinescu SN. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. PLoS One 2010;5(6): e11157.
26. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 2005;280(51):41893-9.
27. Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med 2010;14(3):504-27.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
29. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112 (6):831-43.
30. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007;109(11):5011-5.
31. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ 2nd, et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007; 67(15):7319-26.
32. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105(6):2070-5.
33. Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr. 2007;63(Pt 1):80-93.
34. Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006;26(16): 6082-93.